ArticleCureus2025
Burden of Secondary Hyperparathyroidism Among Patients on Hemodialysis: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Total parathyroidectomy with autotransplantation vs. subtotal parathyroidectomy for secondary hyperparathyroidism: lower recurrence rates but comparable cardiovascular outcomes.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecondary hyperparathyroidism (SHPT) is a frequent complication in patients with end-stage renal disease (ESRD) undergoing hemodialysis. It results from imbalances in calcium, phosphate, and vitamin D metabolism due to impaired renal function.
objectiveThis study aimed to determine the frequency of SHPT among hemodialysis-dependent ESRD patients in a tertiary care hospital in Khyber Pakhtunkhwa.
methodsA cross-sectional study was conducted in the Nephrology Department of Lady Reading Hospital, Peshawar, from August 2023 to January 2024. A total of 127 patients between 18 and 75 years of age, undergoing maintenance hemodialysis for at least six months, were included. SHPT was defined in accordance with the Kidney Disease: Improving Global Outcomes (KDIGO) 2017 guidelines as an intact parathyroid hormone (iPTH) level greater than nine times the upper reference limit in hemodialysis patients. Data were analyzed using IBM SPSS Statistics for Windows, version 25, with stratification based on age, dialysis duration, diabetes status, and hypertension.
resultsOut of 127 patients, 25 (19.7%) were found to have SHPT. The mean age of the study population was 51.8 ± 15 years, with 77 (60.6%) males and 50 (39.4%) females. Diabetes was present in 70 (55.1%) patients, while 83 (65.4%) were hypertensive. SHPT was observed more frequently among male patients, those with a longer duration of dialysis, and individuals with coexisting diabetes and hypertension.
conclusionSHPT was identified in nearly one-fifth of hemodialysis patients, with higher prevalence among males, diabetics, hypertensives, and those on prolonged dialysis. These findings highlight the importance of regular biochemical monitoring and early intervention to reduce SHPT-related complications and improve long-term outcomes in hemodialysis-dependent patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.